Alaunos Therapeutics
TCRT
148 hedge funds and large institutions have $404M invested in Alaunos Therapeutics in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
14% more capital invested
Capital invested by funds: $354M → $404M (+$50.3M)
4% more funds holding
Funds holding: 142 → 148 (+6)
0.02% less ownership
Funds ownership: 0.34% → 0.32% (-0.02%)
49% less call options, than puts
Call options by funds: $5.06M | Put options by funds: $9.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.53M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.34M |
| 3 |
Millennium Management
New York
|
+$5.31M |
| 4 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$2.32M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$5.36M |
| 2 |
Morgan Stanley
New York
|
-$2.19M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.17M |
| 4 |
Rafferty Asset Management
New York
|
-$1.15M |
| 5 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$1.14M |
TCRT Hedge Fund Activity: Q4 2019 in Review
148 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2019, worth a combined $404M — up 14% from $354M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TCRT positions and 20 closed out — a net gain of 7 holders — while 48 added to existing stakes and 34 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.53M. The largest seller was State Street, cutting an estimated $5.36M.
- 148 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2019, up from 142 in Q3 2019.
- Funds reported $404M of Alaunos Therapeutics stock for Q4 2019, up 14% quarter-over-quarter.
- 27 funds opened new Alaunos Therapeutics positions in Q4 2019 and 20 closed out, a net change of +7 holders.
- The largest Alaunos Therapeutics buyer in Q4 2019 was Vanguard Group, an estimated $6.53M added.
- The largest Alaunos Therapeutics seller in Q4 2019 was State Street, an estimated $5.36M sold.
Based on aggregated 13F filings for Q4 2019.